Clinical Trials Browser

Terminated × Has results × eribulin × Clear all

NCT05041101 2025-06-13

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Inflammatory Breast Neoplasms

NCT02681523 2024-09-19

ALERT

Phase 2 Terminated

8 enrolled 20 charts

Breast Neoplasms

NCT03786094 2023-11-01

FORTRESS

Phase 3 Terminated

432 enrolled 13 charts

Breast Neoplasms

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Phase 2 Terminated

2 enrolled 7 charts

Breast Neoplasms

NCT01126749 2022-02-28

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Phase 1/2 Terminated

92 enrolled 15 charts

Urinary Bladder Neoplasms

NCT02753595 2020-07-13

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Phase 1/2 Terminated

25 enrolled 9 charts

Breast Neoplasms

NCT01912963 2018-12-05

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Phase 2 Terminated

32 enrolled 15 charts

Breast Neoplasms

NCT01498588 2016-10-03

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Phase 2 Terminated

7 enrolled 7 charts

Breast Neoplasms

NCT01388647 2015-08-28

Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer

Phase 1/2 Terminated

12 enrolled 12 charts

HER-2 Positive Breast Cancer